Clinical Trial Update: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial compares chemotherapy alone versus chemotherapy plus nivolumab or nivolumab with BMS-986205, followed by continued nivolumab therapy, in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• BMS-986205 (BMS-986205)
• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING